Fulgent Genetics Inc reports results for the quarter ended December 31 - Earnings Summary

• Fulgent Genetics Inc FLGT.OQ reported quarterly adjusted earnings of 4 cents​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of 28 cents. The mean expectation of three analysts for the quarter was for a loss of 12 cents per share. Wall Street expected results to range from -15 cents to -9 cents per share.

• Revenue rose 8.1% to $76.21 million from a year ago; analysts expected $76.09 million.

• Fulgent Genetics Inc's reported EPS for the quarter was a loss of 19 cents​.

• The company reported a quarterly loss of $5.89 million.

• Fulgent Genetics Inc shares had fallen by 15.1% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the healthcare facilities & services peer group is also "hold"

Wall Street's median 12-month price target for Fulgent Genetics Inc is $27.00

This summary was machine generated from LSEG data February 28 at 02:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING	ESTIMATE	ACTUAL	BEAT, MET, MISSED
Dec. 31 2024	-0.12	0.04	Beat
Sep. 30 2024	-0.15	0.31	Beat
Jun. 30 2024	-0.30	0.15	Beat
Mar. 31 2024	-0.32	-0.01	Beat